Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16836696 | 0.89 | MCL1 (0.42) | MCL1MTNR1AMTNR1BBCL2ADAM17 | |
| SCHEMBL16836697 | 0.86 | MMP1 (0.46) | ADAM17MMP1MMP9MMP13 | |
| SCHEMBL16836698 | 0.86 | MMP1 (0.46) | ADAM17MMP1MMP9MMP13 | |
| SCHEMBL18423138 | 0.86 | MMP1 (0.46) | ADAM17MMP1MMP9MMP13 | |
| SCHEMBL16569196 | 0.80 | ADAM17 (0.34) | MAOBADAM17MMP1MMP9MMP13 | |
| SCHEMBL16569198 | 0.80 | ADAM17 (0.34) | MAOBADAM17MMP1MMP9MMP13 | |
| SCHEMBL16836724 | 0.77 | MMP13 (0.34) | ADAM17MMP13 | |
| SCHEMBL16836728 | 0.77 | MMP13 (0.34) | ADAM17MMP13 | |
| SCHEMBL16836727 | 0.75 | MCL1 (0.40) | MCL1MTNR1AMTNR1BBCL2ADAM17 | |
| SCHEMBL16836717 | 0.74 | MTNR1A (0.43) | MCL1MTNR1AMTNR1BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083567-B1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170029411-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-02 | — | — | US | disclosed |
| EP-3083567-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091741-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029411-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | MRPL21, PYM1, DRD3 | MCL1 95/4885MTNR1A 529/4885MTNR1B 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.